Prof. NIE's Team Unveils Promising Hybrid Membrane Nanovaccine for Anti-Tumor Immunotherapy
A team led by Prof. NIE Guangjun has made significant strides in anti-tumor immunotherapy, publishing their innovations in prestigious journals. Their latest development, a hybrid membrane nanovaccine, fuses tumor and bacterial membrane antigens on polymer nanoparticles to activate immune cells.
Prof. NIE's group has previously explored various nanotechnology-based approaches, including nano-inhibitors and OMV-PD1. Their most recent work involves designing personalized tumor vaccines using bacterial and cell membranes, which have shown promising results in mouse models. These vaccines aim to stimulate patients' immune systems to target and destroy tumor cells.
The hybrid membrane nanovaccine is a novel strategy that delivers antigens and adjuvants to provoke robust innate and tumor-specific adaptive immune responses. By fusing tumor membrane antigens with bacterial inner membrane on polymer nanoparticles, the vaccine activates dendritic cells (DCs) and T cells, enhancing the body's defense against cancer.
Prof. NIE Guangjun's team continues to innovate in the field of anti-tumor immunotherapy. Their latest hybrid membrane nanovaccine, which has shown potential in preventing tumor recurrence and providing long-term protection in mouse models, could significantly impact cancer treatment. Further research and clinical trials are needed to validate these promising results.
Read also:
- Overweight women undergoing IVF have a 47% higher chance of conceiving naturally post-weight loss
- Bonsai Trees from Evergreen Species: Exploring Growth Characteristics & Distinct Qualities
- What temperatures may make walking your canine companion uncomfortable?
- Title: Information About Beovu: Potency, Form, Usage, and Additional Details
